Centrient
Sustainable leader in antibiotics, statins and anti-fungals
Centrient Pharmaceuticals is the global business-to-business leader in sustainable, enzymatic antibiotics, next-generation statins and anti-fungals. We produce and sell intermediates and active pharmaceutical ingredients (APIs), as well as our own tablets, capsules and other finished dosage forms (FDFs).
First established in 1869, our story has since been one of constant evolution and innovation. Today, we are a company 2,700-people strong with operations on four continents.
More than this, we are a pharmaceutical company with a clear mission: to improve lives by being at the centre of sustainable and accessible healthcare.
Our company has a common focus that unites each of us in our mission: across our global operations, we are committed to ensuring Quality, Reliability and Sustainability to customers, partners, patients and the world at large.
Moving forward, our vision is to be the leading, diversified and fully integrated partner to generics marketers.
Latest news
Planet B.io is a busy community, we are constantly developing and so are our collaborators, residents and members. To keep everyone updated we write articles and organise events. Take a look!
Meet Aurora Renewable Carbon: turning wood residues into valuable biochemicals
Meet Aurora Renewable Carbon, turning wood residues into renewable sugars and bio-phenolics. By using all three components of wood, Aurora creates multiple valuable chemical feedstocks from a single residual resource.
Meet the Industrial Biotech Bootcamp 2026 cohort
Meet the ventures selected for the 2026 Industrial Biotech Bootcamp, developing biotechnology solutions for more sustainable food, chemicals, materials, water and industrial production.
Joining forces to strengthen the future of cellular agriculture
Cellular Agriculture Netherlands (CAN) has joined Planet B.io as a member, strengthening the Dutch ecosystem for cellular agriculture and industrial biotech. Chair Maresa Oosterman shares why collaboration, shared networks and ecosystem building are essential to help the sector move from breakthrough science to commercial impact.